Fig. 3: SOX2 is a downstream target of SOX2OT in GBM cells. | Cell Death & Disease

Fig. 3: SOX2 is a downstream target of SOX2OT in GBM cells.

From: LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma

Fig. 3

a–b The mRNA and protein expression of SOX2 in TMZ-resistant and its parental cells, *p < 0.05 compared with U87 or U251 cells. c The mRNA expression of SOX2 in different grades gliomas (n = 3), *p < 0.05 compared with the GBM grade I samples. d The protein levels of SOX2 and multi-drug-related genes in various grade gliomas (n = 3). e The protein expression of SOX2 in various glioma cell lines was detected via western blot analysis, compared with the normal human astrocytes (NHA). f–g The SOX2 expression levels in U87 or U251 cells under different TMZ concentrations was measured through qRT-PCR and western blot assay. *p < 0.05 or &p < 0.05 compared with no TMZ groups. h–i The SOX2 expression was detected via qRT-PCR or western blot assay after transfection with sh-SOX2OT or LV-SOX2OT lentiviral vectors, *p < 0.05 compared with sh-NC or LV-NC group. j Co-transfection of LV-SOX2OT reversed the protein level of SOX2 knockdown, whereas co-expression of sh-SOX2OT abrogated the effects induced by LV-SOX2 in GBM cells. k SOX2 expression levels in primary and relapsed GBM tissues were examined by qRT-PCR and normalized against U6 expression, primary GBM (n = 36), relapsed GBM (n = 39), ****p < 0.0001 compared with primary GBM tissues. l The relationship of SOX2OT and SOX2 expression in 75 GBM tissues through qRT-PCR analysis.

Back to article page